Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia

In sickle cell disease (SCD), hydroxyurea (HU) treatment decreases the number of vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) by increasing fetal hemoglobin (HbF). Data are lacking regarding the frequency of HU dose modification or whether sub-therapeutic doses (<15 mg/kg/day) are b...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Mol Sci
Main Authors: Di Maggio, Rosario, Hsieh, Matthew M., Zhao, Xiongce, Calvaruso, Giuseppina, Rigano, Paolo, Renda, Disma, Tisdale, John F., Maggio, Aurelio
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5877542/
https://ncbi.nlm.nih.gov/pubmed/29495591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms19030681
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki